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Introduction
It is well known that chronic headaches, of which the ten-
sion-type form is the one with the greatest epidemiologi-
cal prevalence [1], have a strong impact in terms of
“Quality Of Life” (QOL) and socio-economic costs [2].
At present, amitriptyline represents the first choice in
prophylactic therapy of chronic tension-type headache
(CTTH), supported by the highest levels of evidence [3].
As is well known, the effectiveness of amitriptyline in
CTTH prophylaxis may be observed only after 2–3 weeks
of therapy, with a consequent persistence of the headache
and its correlated negative impact on psychophysical con-
ditions in the first phases of treatment. In this respect, a
faster pharmacological treatment would be very useful.
Many clinical trials indicate tizanidine as a promising
additional prophylactic agent in chronic headaches, while
currently available data do not justify its use in monother-
apy [3, 4]. Tizanidine is an α2 agonist that inhibits the
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Abstract Chronic tension type
headache (CTTH) has a strong
impact on the Quality Of Life
(QOL). We carried out an open-label
randomized clinical trial on 18
patients with CTTH in order to com-
pare two different regimens of phar-
macological prophylaxis: the first
provided for the use of amitriptyline
20 mg/d during 3 months, while in
the second we combined  amitripty-
line with tizanidine (4 mg/d) in the
first 3 weeks of treatment.
Our hypothesis is that the combina-
tion therapy may guarantee an
improvement of QOL even in the
early stages of treatment. In fact, it’s
as well-known, there is a delay of
2–3 weeks in the prophylactic effect
of amitriptyline , with a consequent
persistence, in the first phases of
therapy, of the headache and its neg-
ative impact.
We assessed the following outcome
measures: frequency, pain intensity,
duration of headache and the
Headache Impact Test (HIT) score,
used as headache-related QOL mea-
sure. The combination therapy was
effective since the first month of
treatment, with a significant reduc-
tion of the headache, greater than
one obtained with  amitriptyline
alone, in terms of frequency (-52,3%
vs. -40,7%), intensity (-59,51%
vs. -20,39%) and duration (-53,17%
vs. -36,16%).
This trend was confirmed by the
HIT. Our data suggest that the com-
bination of tizanidine with amitripty-
line  is  faster than the amitriptyline
alone in providing an improvement
in the headache pattern and correlat-
ed QOL.
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release and effect of norepinephrine in both the brainstem
(e.g., locus coeruleus) and the spinal cord. It acts as a cen-
tral muscle relaxant but it also has an antinociceptive
effect that does not involve the endogenous opioid system
and appears to be centrally mediated by α2 adrenorecep-
tors, with little, if any, interaction with 5-HT, dopamine
and GABA receptors [4].
There is not a codified posology for headache prophy-
laxis with tizanidine. In clinical trials it was used at a
dosage between 2 and 24 mg/day, for periods varying
from 2 to 12 weeks [5–7]. Unlike amitriptyline, tizanidine
does not have a latency period of clinical effects, neither
as an antispastic nor in the prophylaxis of cephalalgia [4].
We carried out an open-label clinical trial in order to
evaluate the effectiveness and the impact on QOL of a com-
bined treatment with tizanidine and amitriptyline in the first
weeks of the pharmacological prophylaxis of CTTH. The
aim of our study was to determine if the combination tizani-
dine/amitriptyline may have, as expected from a pharmaco-
dynamic standpoint, a faster action than amitriptyline alone
in both reducing the cephalalgical pattern, and consequent-
ly, in improving the headache-related QOL.
Patients and methods
All consecutive patients (n=27) who had been diagnosed with
CTTH according to the International Headache Society criteria in
the six months prior to the study were preliminarily evaluated.
Subjects with coexistence of migraine (IHC criteria) and CTTH
were excluded. After an observation period of one month, in
which patients recorded their headache pattern in a baseline stan-
dard diary, 18 patients (5M, 13F, mean age 35.2±11) were enrolled
in the study. All patients had normal neurological examination and
laboratory investigation. They did not show any other health prob-
lems, or contraindications to the use of the drugs in question.
Depression had been ruled out at the time of recruitment using the
Zung test. Abortive treatment with a simple analgesic was permit-
ted, but we excluded the abusers (IHC criteria) [8]. The sympto-
matic drugs used in our population were paracetamol and non-
steroidal anti-inflammatory drugs, with a mean use of abortive
medication of 11.15±3.49 days/month in the observation period.
Patients at the run-in were randomized, via an online random
number generator (http://www.randomizer.org), into two groups of
treatment, each one consisting of 9 patients. The first (A group, 2M,
7F, average age 34.5±12.2) assumed amitriptyline 20 mg/day for 3
months, while the second (B group, 3M, 6F, mean age 36±9.8) was
treated with amitriptyline 20 mg/day for 3 months combined with
tizanidine (4 mg/day) in the first 21 days of treatment.
Using a standard headache diary/4 weeks, drawn up by the
patient, we collected the following outcome measures: number
of headache days per month, pain intensity with a numerical
score (1, mild headache, easily ignored; 2, moderate, tolerable;
3, very intense pain/intolerable) and duration of headache in
hours. The headache-related QOL was assessed monthly with the
HIT6 questionnaire [9].
In both groups, monthly headache frequency, mean intensity,
mean headache duration and HIT scores were assessed using
data from standard headache diary/4 weeks of both pre-treatment
month (T0 period – baseline) and two treatment periods (weeks
1–4 [T1 period] and weeks 9–12 [T2 period]).
For each group of treatment, we assessed the mean per cent
reduction of each variable obtained in T1 and T2 evaluation with
the mean baseline value. Thereafter we compared the results in
the two treatment groups. Statistical evaluation was performed
with the χ2-test, deeming a p value <0.05 as significant.
Results
All 18 patients enrolled completed the study. In our
patients the combination therapy (B group: tizanidi-
ne+amitriptyline) was effective from the first month of
treatment, with a significant reduction of symptoms
(>50%) in terms of frequency, intensity and duration of
the headache. This reduction was greater than the one
obtained with amitriptyline alone (A group).
In particular, in the first four weeks of treatment we
recorded the following per cent improvement in headache
indexes (Tables 1 and 2): frequency -52.3% in B group vs.
-40.7% in A group (p<0.05), intensity -59.51% vs. -20.39%
(p<0.02), duration -53.17% vs. -36.16% (p<0.05). At the
end of the 90-day treatment period, however, there were no
significant differences (frequency -57.71% in B group vs. -
60.04% in A group; intensity -30.05% vs. -23.81%; and
duration -56.55% vs. -37.55%; all results with p>0.05).
Table 1 Results of prophylaxis with amitriptyline alone
Group A: amitriptyline Mean headache, Mean pain, Mean duration, HIT,
days/4 weeks±SD intensity±SD h±SD 6±SD
T0 20.32±3.43 1.68±0.19 6.95±3.05 61.26±2.46
T1 12.05±3.59 1.34±0.26 4.44±2.25 53.37±2.57
T2 8.12±3.63 1.28±0.51 4.34±2.36 47.71±15.28
Mean improvement % (T0–T1) -40.70% -20.39% -36.16% -12.88%
Mean improvement % (T0–T2) -60.04% -23.81% -37.55% -22.11%
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This trend of improvement had also been confirmed by
the pattern of HIT scores, which are an indicator of the
headache impact on QOL (-18.56% vs. -12.88% in T1 peri-
od, p<0.05; at the 3rd month -23.20 vs. -22.11, p>0.05).
Three patients (33.3%) from group A and four patients
(44.4%) from group B reported mild to moderate common
adverse events such as somnolence (22.2%, n=2 in A group
and 33.3%, n=3 in B group), asthenia (11.1%, n=1 in A group
and 22.2%, n=2 in B group), dry mouth (2 patients, 22.2% in
A group) and dizziness (only 1 patient, 11.1% in B group).
Discussion
Our data, although obtained from a small group of pa-
tients, suggest that adding tizanidine to amitriptyline in
the first phase of treatment provides a more rapid im-
provement in the headache pattern, compared to the use of
amitriptyline alone. As expected, the faster effectiveness
of combination therapy had an immediate impact on the
headache-related quality of life. Furthermore, the use of
tizanidine in addition to amitriptyline was well tolerated.
In our opinion, the high frequency and the remarkable
disability correlated with CTTH suggest the need for a
prophylaxis treatment which is not only effective, but also
as fast as possible in restoring an acceptable QOL from
the first days of treatment.
This preliminary study suggests that the combination
of amitriptyline and tizanidine has a promising potential
as a therapeutic option in the preventive treatment of
CTTH. A large double-blind randomised controlled trial
would be needed in order to draw strong evidence on this
issue.
Table 2 Results of use of tizanidine in addiction to amitriptyline
Group B: amitriptyline+tizanidine Mean headache, Mean pain, Mean duration, HIT,
days/4 weeks±SD intensity±SD h±SD 6±SD
T0 21.80±4.76 1.83±0.28 8.05±2.79 62.50±3.41
T1 10.40±5.89 1.29±0.37 3.77±2.00 50.90±3.54
T2 9.22±7.00 1.28±0.51 3.49±2.47 48.00±6.32
Mean improvement % (T0–T1) -52.30% -59.51% -53.17% -18.56%
Mean improvement % (T0–T2) -57.71% -30.05% -56.65% -23.20%
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